HC Wainwright reiterated their buy rating on shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in a report issued on Friday. They currently have a $6.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on CPRX. Piper Jaffray Companies set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 7th. Roth Capital set a $5.00 price target on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 10th. SunTrust Banks, Inc. set a $5.00 price target on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 31st. Finally, Zacks Investment Research cut shares of Catalyst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $5.50.

Shares of Catalyst Pharmaceuticals (CPRX) traded down $0.12 during midday trading on Friday, hitting $2.87. 2,011,700 shares of the company traded hands, compared to its average volume of 872,389. Catalyst Pharmaceuticals has a one year low of $1.01 and a one year high of $3.24.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/11/catalyst-pharmaceuticals-inc-cprx-receives-buy-rating-from-hc-wainwright.html.

In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany acquired 20,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were acquired at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the acquisition, the insider now owns 4,471,026 shares in the company, valued at $11,535,247.08. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.79% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Catalyst Pharmaceuticals by 11.3% in the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock worth $9,242,000 after purchasing an additional 340,614 shares during the period. JPMorgan Chase & Co. grew its holdings in Catalyst Pharmaceuticals by 1,833.2% in the second quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock worth $4,240,000 after purchasing an additional 1,456,830 shares during the period. State Street Corp grew its holdings in Catalyst Pharmaceuticals by 1,971.1% in the second quarter. State Street Corp now owns 938,195 shares of the biopharmaceutical company’s stock worth $2,590,000 after purchasing an additional 892,895 shares during the period. Kennedy Capital Management Inc. grew its holdings in Catalyst Pharmaceuticals by 298.5% in the second quarter. Kennedy Capital Management Inc. now owns 918,438 shares of the biopharmaceutical company’s stock worth $2,535,000 after purchasing an additional 687,938 shares during the period. Finally, Northern Trust Corp grew its holdings in Catalyst Pharmaceuticals by 620.9% in the second quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock worth $2,215,000 after purchasing an additional 691,238 shares during the period. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Stock Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.